QurieGen
Develops genomic and biological tools for personalised health monitoring and performance optimisation.
Funding
€100,000 non-dilutive grant
Standard DIANA Phase 1 grant. Phase 2 offers up to €300,000 for outstanding performers.
Programme track
Part of NATO DIANA's network of 16 accelerator sites and 200+ test centres.
Facts
- Cohort
- 2025 Cohort
- Challenge area
- Human Health & Performance
- Country
- Netherlands
- Funding stage
- €100,000 non-dilutive grant
- Website
- quriegen.com
- Verification
- Verified against official DIANA announcements
Sources and verification
Selection facts (cohort, challenge area, funding track) come from the DIANA 2025 cohort announcement (December 2024). Company descriptions are paraphrased from public company material. How we verify records is explained in the methodology. Data reviewed 2026-08-23.
Data reviewed 2026-08-23. See our methodology for sourcing and verification rules.